Key Takeaways
- • Executive expansion effective October 1, 2026: Patrick Schlump joins HELIX alpha as Managing Partner to strengthen investment and fund management operations, bringing multi-decade experience in European institutional real estate investment across healthcare and alternative asset classes.
- • Advisory division launch: HELIX alpha is expanding beyond its core investment management business to offer advisory services, leveraging existing internal expertise in life science real estate to serve external institutional mandates.
- • Leadership transition: Dr. Thomas Diefenthal transitions from the advisory board to operational role as Director Advisory, bringing BioPark Regensburg management experience and joining the Investment & Risk Committee.
- • Proven track record of collaboration: Schlump and HELIX alpha CEO Martin Eberhardt have worked together since 2009 across multiple pan-European real estate platforms, including Union Investment, Bouwfonds Investment Management, and Swiss Life Asset Managers, developing institutional investment strategies in emerging real estate segments.
- • European life science platform consolidation: The moves position HELIX alpha to deepen its specialization in European life science real estate while broadening service offerings to institutional investors through a dual investment management and advisory model.
Summary
HELIX alpha, a specialized European life science real estate platform, is strengthening its management structure and expanding service capabilities as of October 1, 2026. Patrick Schlump will assume the role of Managing Partner, reinforcing the firm's investment and fund management functions while enhancing institutional investor support. Concurrently, HELIX alpha is launching an advisory division that complements its core investment management business.
Schlump brings substantial experience in European institutional real estate investment management. Most recently, he served at Praemia REIM, a pan-European healthcare real estate investment manager. His relationship with HELIX alpha founder and CEO Martin Eberhardt extends back to 2009, when both worked together across multiple established platforms including Union Investment, Bouwfonds Investment Management, and Swiss Life Asset Managers' subsidiary Corpus Sireo. During these collaborative roles, both were instrumental in developing and launching pan-European institutional real estate investment products across emerging segments, including multi-storey car parks and student housing—areas not yet established among professional investors at the time.
Dr. Thomas Diefenthal is transitioning from HELIX alpha's advisory board to an operational position as Director Advisory, following his tenure as Managing Director of BioPark Regensburg GmbH. In this new capacity, he will contribute his expertise to the firm's Investment & Risk Committee while directing the newly launched advisory function.
The advisory expansion is designed to leverage existing internal expertise in life science real estate without diluting investment management's role as the platform's strategic core. The dual-service model positions HELIX alpha to serve external institutional mandates while maintaining its focus on specialized European life science real estate investment.
Schlump brings substantial experience in European institutional real estate investment management. Most recently, he served at Praemia REIM, a pan-European healthcare real estate investment manager. His relationship with HELIX alpha founder and CEO Martin Eberhardt extends back to 2009, when both worked together across multiple established platforms including Union Investment, Bouwfonds Investment Management, and Swiss Life Asset Managers' subsidiary Corpus Sireo. During these collaborative roles, both were instrumental in developing and launching pan-European institutional real estate investment products across emerging segments, including multi-storey car parks and student housing—areas not yet established among professional investors at the time.
Dr. Thomas Diefenthal is transitioning from HELIX alpha's advisory board to an operational position as Director Advisory, following his tenure as Managing Director of BioPark Regensburg GmbH. In this new capacity, he will contribute his expertise to the firm's Investment & Risk Committee while directing the newly launched advisory function.
The advisory expansion is designed to leverage existing internal expertise in life science real estate without diluting investment management's role as the platform's strategic core. The dual-service model positions HELIX alpha to serve external institutional mandates while maintaining its focus on specialized European life science real estate investment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.